Wohl & Fruchter LLP is investigating the fairness of Cross Country Healthcare's proposed sale to private equity firm Knox Lane at $13.25 per share, which is below its 52-week high and a previously agreed $18.61 per share offer from Aya Healthcare that was terminated. The law firm questions whether the CCRN board acted in shareholders' best interests and fully disclosed all material information. CCRN shareholders with concerns are encouraged to contact the firm for legal advice at no charge. This investigation highlights potential shareholder disputes over the sale price and transparency of the transaction.
Jefferies analysts set a new price target of $435 for General Electric Aerospace, implying a 35% upside from its current price of around $321. GE Aerospace's strong position is supported by a $170 billion commercial services backlog and 80,000 aircra...
BNP Paribas lowered its price target for PepsiCo from $183 to $161 on September 23, 2026, due to ongoing demand challenges in North America. Despite the cut, the firm maintained an Outperform rating, indicating confidence in the stock's potential. Th...
Celldex Therapeutics saw its price target raised from $70 to $88 by Leerink Partners following successful Phase III trial results for its drug barzolvolimab treating chronic spontaneous urticaria (CSU). The trials met all primary endpoints, showing l...
Ero Copper, a major copper producer, shows stock volatility between $16.88 and $40.83 over the past year. Analyst firm CIBC maintained a "Neutral" rating but increased the price target to C$56.00, reflecting optimism about the company's long-term gro...
Cintas Corporation posted robust first-quarter results, surpassing analyst expectations with earnings per share of $1.39 and revenue of $3.01 billion, a 10.9% increase year-over-year. The company's organic revenue growth was 8.9%, reflecting solid bu...
